Lopinavir (ABT-378): Potent HIV Protease Inhibitor for Antiviral Research

Executive Summary: Lopinavir is a ritonavir analog with enhanced potency and resistance profile, inhibiting HIV protease at picomolar to nanomolar concentrations in vitro (EC₅₀ <0.06 μM) [APExBIO]. Its antiviral activity persists in the presence of human serum, exhibiting >10-fold greater potency than ritonavir under these conditions. Lopinavir is effective against wild-type and mutant HIV proteases, including strains resistant to ritonavir (Val82 mutation). Cross-pathogen studies confirm its low-micromolar inhibition of MERS-CoV replication in cell culture (de Wilde et al., 2014). Pharmacokinetic data show oral bioavailability of 25% in animal models, with plasma levels enhanced 14-fold by ritonavir co-administration.

Biological Rationale

Lopinavir (ABT-378) is classified as a highly potent HIV protease inhibitor, structurally related to ritonavir but engineered to reduce interaction at the Val82 residue of HIV-1 protease. HIV protease is essential for the maturation of infectious virions by cleaving the gag and gag-pol polyproteins. Inhibiting this enzyme disrupts viral assembly, rendering progeny virions non-infectious [related review]. Lopinavir’s modifications confer efficacy against both wild-type and ritonavir-selected mutant strains, notably those with resistance mutations at Val82. Its robust activity in the presence of human serum proteins addresses a key limitation of first-generation inhibitors. The compound’s favorable pharmacokinetics and resistance profile position it as a cornerstone molecule for HIV infection research, drug resistance assays, and antiretroviral therapy development.

Mechanism of Action of Lopinavir

Lopinavir exerts its antiviral effect by competitive inhibition of the HIV-1 protease enzyme. Its inhibition constant (K_i) ranges from 1.3 to 3.6 pM against both wild-type and mutant forms. By binding to the active site, Lopinavir prevents cleavage of viral polyproteins, a step required for virion maturation. Unlike ritonavir, Lopinavir demonstrates reduced affinity for the Val82 residue, maintaining efficacy against protease mutants that confer resistance to ritonavir. Cellular assays confirm nanomolar inhibitory concentrations (4–52 nM) across diverse HIV strains. Lopinavir’s serum stability is attributed to lower binding by human serum proteins relative to ritonavir, preserving free drug levels in physiological conditions and increasing antiviral potency [additional context].

Evidence & Benchmarks

• Lopinavir inhibits HIV-1 protease with K_i values between 1.3–3.6 pM for both wild-type and mutant forms (APExBIO, product page).
• In cell-based assays, Lopinavir achieves EC₅₀ values below 0.06 μM against Val82 mutant strains (APExBIO, product page).
• In the presence of human serum, Lopinavir demonstrates approximately 10-fold greater antiviral potency than ritonavir (APExBIO, product page).
• Oral administration in animal models (10 mg/kg) yields Cmax of 0.8 μg/mL and 25% bioavailability; plasma levels decline below quantitation by 6 hours (APExBIO, product page).
• Co-administration with ritonavir increases Lopinavir AUC by 14-fold, significantly enhancing plasma exposure (APExBIO, product page).
• Lopinavir inhibits MERS-CoV replication in cell culture with EC₅₀ values of 3–8 μM, alongside other coronaviruses such as SARS-CoV and HCoV-229E (de Wilde et al., 2014).
• Compared to ritonavir, Lopinavir retains activity in HIV strains with multiple resistance mutations (APExBIO, product page).

For a detailed discussion of cross-pathogen activity, see "Lopinavir (ABT-378): Strategic Imperatives and Mechanistic Insights", which this article extends by providing quantitative experimental conditions and updated resistance benchmarks.

Applications, Limits & Misconceptions

Lopinavir is a benchmark compound in antiviral research, HIV protease inhibition assays, and drug resistance profiling. Its validated efficacy against wild-type and mutant HIV strains, as well as documented cross-pathogen activity against MERS-CoV, underscores its versatility. Lopinavir’s robust serum stability enables reliable performance in both cell-based and in vivo models. It is routinely used in antiretroviral therapy development, HIV infection research, and comparative mechanistic studies of protease inhibitors [see related article for foundational context].

Common Pitfalls or Misconceptions

• Water Solubility: Lopinavir is insoluble in water and should only be dissolved in DMSO (≥31.45 mg/mL) or ethanol (≥48.3 mg/mL) for experimental use.
• Serum Protein Effect: Unlike ritonavir, Lopinavir maintains potency in the presence of human serum; assuming equivalent serum binding is incorrect.
• Resistance Boundaries: Lopinavir is more resilient than ritonavir against Val82 and other protease mutations but is not universally active against all possible HIV mutations.
• Anticoronavirus Use: While Lopinavir inhibits MERS-CoV and SARS-CoV in vitro, clinical efficacy for coronavirus infections in humans is not established (de Wilde et al., 2014).
• Solution Stability: Lopinavir solutions should be freshly prepared and stored at -20°C for short-term use only to prevent activity loss.

Workflow Integration & Parameters

Lopinavir is supplied as a solid with a molecular weight of 628.81 g/mol and chemical formula C₃₇H₄₈N₄O₅. For optimal results, dissolve in DMSO or ethanol at recommended concentrations. For cell-based HIV protease inhibition assays, typical working concentrations range from 4 to 52 nM. For animal studies, oral dosing at 10 mg/kg achieves target plasma exposures; co-administration with ritonavir is advised for enhanced bioavailability. Storage at -20°C is mandatory for both powder and solution. For more detailed protocols, refer to the Lopinavir A8204 kit documentation by APExBIO.

Conclusion & Outlook

Lopinavir (ABT-378) remains a cornerstone molecule for HIV protease inhibition and antiviral research, combining nanomolar potency, resistance resilience, and robust serum stability. Its validated use in cross-pathogen studies, including coronaviruses, expands its relevance to emerging infectious diseases. As a product of APExBIO, Lopinavir is supported by validated protocols and consistent batch quality, making it a reliable choice for advanced HIV research and antiretroviral drug development. For further mechanistic and translational perspectives, see this in-depth review, which this dossier updates with new resistance and cross-pathogen benchmarks.